All Q1 FY27 results →

NP

Natco Pharma

Q1 FY27

Natco Pharma Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹785

Market cap₹15.4K Cr

P/E13.5

Updated16 Oct 2026

Read4 min read

What the Q1 FY27 call signalled

3 of 4 strong

RevenueGood growth

MarginMargins steady

CapexCapex planned

FundraiseFundraise planned

The short version

Domestic formulations expected to grow about 25% in volume this year (Page 4). - Brazil business showing strong growth with revenue at INR178 crores, up 180% (Page 3). - Growth anticipated across key geographies: Brazil, Canada, and the U.S. PAT guidance for FY27 remains around INR 750 crores, with no change despite seasonal fluctuations.

From Natco Pharma's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Good growth

Domestic formulations expected to grow about 25% in volume this year (Page 4).
Brazil business showing strong growth with revenue at INR178 crores, up 180% (Page 3).
Growth anticipated across key geographies: Brazil, Canada, and the U.S. (Page 6).
New product launches in Brazil planned for FY27, driven by oncology pipeline (Page 8).
Expect growth in international formulations supported by product launches and pipeline expansion (Page 9).
Overall revenue guidance for the year: gross sales between INR3,300 crores to INR3,400 crores and total sales around INR750 crores PAT (Page 6).

2 more points from Natco Pharma's call on revenue

Create a free account to keep reading this call

Profitability & Margins

PAT guidance for FY27 remains around INR 750 crores, with no change despite seasonal fluctuations. (Page 11)
Domestic business expects around 25% volume growth this year, aided by semaglutide and oncology segments. (Page 5)
Export revenues expected to grow with strong performance across Brazil, Canada, U.S., and other markets. (Pages 5-7)
R&D investments target 8-10 ANDA filings annually, with 2-3 first-to-file (FTF) expected to drive future growth. (Page 13)
Long-term R&D spends (8-10 years horizon) likely yield 20x to 40x returns; shorter-term investments yield moderate returns. (Page 14)

2 more points from Natco Pharma's call on margins

Create a free account to keep reading this call

See what Natco Pharma said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned

NATCO plans to continue organic capex at an annual run rate of approximately INR 250-300 crores for capacity expansion and internal requirements.
The company is also evaluating various acquisition opportunities, both in India and internationally, requiring additional capital.
A proposed fundraise of INR 2,000 crores is intended to support potential acquisitions, pay off short-term loans, and cover ongoing capex.
Capex investments target readiness for growth opportunities already under evaluation.
Strategic investments include pipeline development and expanding registration capabilities, especially for 9(3) limited competition products.

2 more points from Natco Pharma's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

NATCO Pharma is planning to raise INR 2,000 crores through the market.
Various options are being evaluated for the fundraising, including QIP (Qualified Institutional Placement), rights issue, or others.
The company is exploring all options and will choose the right method based on what fits best.
The fundraise is intended to support internal capex (~INR 250-300 crores annually), pay off short-term loans, and fund potential acquisitions and inorganic growth opportunities.
Opportunities exist both within India and internationally.

2 more points from Natco Pharma's call on fundraising

Create a free account to keep reading this call

See what Natco Pharma said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant insights include: - The company is actively engaged in multiple markets including India, South Africa, Brazil, Canada, and the U.S., indicating ongoing and future demand. - There are different product cycles and seasonality impacting order flow (e.g., flu season boosting Adcock’s sales in South Africa). - The company has ongoing registration filings and expected product launches, such as semaglutide in South Africa (expected around 2028). - The business is evaluating acquisition opportunities indicating potential for increased future order inflows.

2 more points from Natco Pharma's call on order book

Create a free account to keep reading this call

Natco Pharma — Quarterly revenue & net profit

Revenue Net profit

Sep 2024Q2 FY25

Dec 2024Q3 FY25

Mar 2025Q4 FY25

Jun 2025Q1 FY26

Sep 2025Q2 FY26

Dec 2025Q3 FY26

Q1 FY27 figures are not in this chart yet. Latest shown: Dec 2025 (Q3 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹647 Cr, net profit ₹151 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Natco Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Natco Pharma and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Natco Pharma Q1 FY27 results?

Domestic formulations expected to grow about 25% in volume this year (Page 4). - Brazil business showing strong growth with revenue at INR178 crores, up 180% (Page 3). - Growth anticipated across key geographies: Brazil, Canada, and the U.S. PAT guidance for FY27 remains around INR 750 crores, with no change despite seasonal fluctuations.

What is Natco Pharma share price analysis?

Natco Pharma currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 13.5 with a market cap of ₹15,400 Cr. Investors should review the full earnings analysis for detailed insights.

Is Natco Pharma planning capital expenditure?

NATCO plans to continue organic capex at an annual run rate of approximately INR 250-300 crores for capacity expansion and internal requirements.

Keep Natco Pharma on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.